{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.3","upperLimit":"26.2","value":"10"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"description":"A responder is defined as a patient who achieves a best response of partial response or complete response on the study. Response rates will be calculated as the percent of evaluable patients who are responders. The revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1) was used to determine response and progression in this study, with specific criteria outlined for the different subtypes of tumors (e.g., 2-dimensional measurements for central nervous system (CNS) tumors).","dispersionType":"90% Confidence Interval","groups":[{"description":"Patients receive erdafitinib PO QD on days 1-28 of each cycle. Treatment repeats every 28 days for up to 26 cycles (2 years) in the absence of disease progression or unacceptable toxicity. Patients undergo an x-ray, CT scan, MRI, PET scan, radionuclide imaging, and/or bone scan, as well as a bone marrow aspiration and/or biopsy during screening and on study. Patients also undergo blood sample collection on study.","id":"OG000","title":"Treatment (Erdafitinib)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 2 years from study entry","title":"Objective Response Rate","type":"PRIMARY","unitOfMeasure":"percentage of patients"}